BioMarin has reported that the multi-centre Phase III PEGASUS trial of Palynziq (pegvaliase-pqpz) has met its primary ...

The ‘Trade of the Day’ is now live. Get a high-probability setup with clear entry and exit points right here. PKU is a rare, ...

BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that the Phase 3 PEGASUS trial evaluating PALYNZIQ® (pegvaliase-pqpz) met its primary efficacy endpoint, demonstrating a statistically ...

SHENZHEN, China, April 3, 2025 /PRNewswire/ -- The 2025 PKU Shenzhen Forum, organized by Peking University HSBC Business ...

PKU is a genetic disease that manifests at birth and results from an inability to break down phenylalanine (phe), an amino acid that is commonly found in many foods. Left untreated, high levels of ...

Shares in Synlogic have halved in value after the company reported that a phase 3 trial of its main pipeline drug for rare metabolic disorder phenylketonuria (PKU) failed to show efficacy ...

Organised jointly by LSE and Peking University (PKU), this double master’s degree offers an outstanding opportunity for graduate students and young professionals to study the international relations ...